Qu Biologics.png
Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis
May 12, 2021 09:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
22157.jpg
China Pembrolizumab Market Report 2021: Market Size will Expand in the Future Due to the Increased Numbers of Approved Indications
April 19, 2021 08:18 ET | Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Pembrolizumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. After Pembrolizumab...
22157.jpg
Global Bi-Specific MAbS Market Report 2020: Market is Expected to Stabilize and Reach $6.12 Billion by 2023 - Long-term Forecast to 2025 & 2030
March 25, 2021 06:43 ET | Research and Markets
Dublin, March 25, 2021 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Bi-Specific...
Logo.jpg
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
March 19, 2021 08:45 ET | Celsion CORP
Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins at 11:00 a.m. Eastern Time Today ...
22157.jpg
Worldwide BiTE Antibodies Industry to 2025 - Players Include Amgen, Bayers & Micromet Among Others
February 23, 2021 05:38 ET | Research and Markets
Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. This...
22157.jpg
Global Advanced Antibodies Report 2020 with Profiles of Key Companies - Advances in Antibody-based Therapies, Bispecific Antibodies (bsAbs) have Gained Momentum
January 21, 2021 07:03 ET | Research and Markets
Dublin, Jan. 21, 2021 (GLOBE NEWSWIRE) -- The "Advanced Antibodies, 2020" report has been added to ResearchAndMarkets.com's offering. This report profiles companies (excluding Tier 1...
Qu Biologics.png
Qu Biologics Completes $8M Financing
December 09, 2020 06:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
provectus_logo.jpg
Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
September 17, 2020 06:00 ET | Provectus Biopharmaceuticals Inc.
62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient...
CLS-Logo-1.jpg
CLS and Advanced Medical Systems Form Joint Venture Cooperation, Introducing the Innovative TRANBERG® Thermal Therapy System and imILT® in the Asia-Pacific Region
August 24, 2020 03:00 ET | Clinical Laserthermia Systems Americas, Inc.
LUND, Sweden, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), developer of innovative image-guided laser ablation technology for minimally invasive soft tissue and...
Qu Biologics.png
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
August 18, 2020 14:35 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...